novartis ag-2nd line
(NOVNEE:SIX Swiss Ex)
Transactions by NOVARTIS AG-2ND LINE (NOVNEE) in the last 6 months
Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
Caribou Biosciences, Inc. announced that it has received undisclosed amount in series A round of equity funding from Novartis AG on January 7, 2015.
Mission Bay Capital LLC
Intellia Therapeutics announced that it has received $15 million in its first round of funding from new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.
|Gilead Sciences Inc||$105.01 USD||+4.50|
|Johnson & Johnson||$100.13 USD||+0.93|
|Merck & Co Inc||$59.86 USD||+0.30|
|Pfizer Inc||$34.08 USD||+0.15|
|Roche Holding AG||SFr.269.40 CHF||+1.00|
|View Industry Companies|